MedPath

BCR-ABL Peptide Vaccination in Normal Subjects.An investigation in normal subjects with HLA-A3 and HLA-B8, as an extension of an identical study in patients with Chronic Myeloid Leukaemia. - BCR-ABL Peptide Vaccination in Normal Subjects.

Phase 1
Conditions
Healthy Subjects
Registration Number
EUCTR2005-001745-42-GB
Lead Sponsor
niversity of Liverpool and Royal Liverpool University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
Not specified
Target Recruitment
20
Inclusion Criteria

Aged 18 or over and previously a volunteer apheresis blood donorAble to give informed written consent.HLA-A3 and/or –B8 positiveNot currently donating to the National Blood ServiceNo serious concomitant illness (eg heart disease) that might preclude completion of the study.Serum creatinine, alanine transaminase and blood count within normal limits.Negative pregnancy test in women of childbearing age.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Pregnancy or lactatingReceiving steroids or other immunosuppressive agentsCurrently donating to National Blood Service

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath